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ABSTRACT 
 The ability of HIV-1 to interact with receptors on the host cell plays a major role in 
determining its tropism.  Several point variations in the envelope gene of clade B R5 viruses 
have been shown to confer tropism towards primary macrophages.  The T283N mutation in the 
CD4bs of HIV has been shown to drastically affect macrophage tropism.  More recently an 
E153G mutation located in the V1 loop which modulates the V3 loop to prime low CD4 use 
has also been shown to confer high levels of macrophage infectivity.  This shift may also 
increase the envelopes sensitivity to neutralizing antibodies.  This project explores whether these  
residues involved in the non-macrophage-tropic phenotype of transmitted R5 viruses or effect 
sensitivity to entry inhibitors, soluble CD4, b12 and Maraviroc.  The results presented confirm 
that substitutions at 153 and 283 affect macrophage-tropism of some viruses and/or shift 
sensitivity to entry inhibitors. Importantly, my data implicates the presence of further, unknown 
and dominant determinants of non-macrophage-tropism. 
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BACKGROUND 
H I V  H i s t o r y  
The Human Immunodeficiency Virus (HIV) is a retroviral lentivirus which leads to 
Acquired Immunodeficiency Syndrome (AIDS) in humans.  HIV is a retrovirus characterized by 
a long and variable incubation period.  The first clinical observations of AIDS like symptoms, 
known at the time as Pneumocystis carinii pneumonia (PCP), were published in 1981 (Drew, 
1981).  This was then linked to a rare form of skin cancer known as Kaposi’s sarcoma (KS) and 
eventually led to the discovery of a new retrovirus initially named HTLV-III but later renamed 
HIV.  Since its discovery the virus has infected and killed many millions leading to it being 
considered a pandemic by the World Health Organization. Currently, there are at least 33.3 
million people infected with HIV (UNAIDS, 2010). 
 
Figure 1: Global HIV Pandemic.  The world health organization 2009 report 
shows that the worldwide pandemic has reached 33.3 million since its discovery 
in the 1980’s (UNAIDS, 2010). 
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P a t h o l o g y  o f  H I V  I n f e c t i o n  
 The HIV virus is thought to have originated in non-human primates and transferred to 
humans in Sub-Saharan Africa more than a century ago.  Two main variants of the virus have 
been found, HIV-1 which is the cause of most of the cases worldwide and HIV-2 which is less 
virulent and is found mostly in West Africa (Coffin, 1997).  Both are closely related to Simian 
Immunodeficiency Virus (SIV) with HIV-1 being more closely linked with SIVcpz which infect 
chimpanzees and HIV-2 being more close to SIVsmm which infects sooty mangebey monkeys 
(Knipe and Howley, 2001).  HIV is divided into 3 groups: M – the main group, O – an outlier 
group, and N – the group being neither M nor O.  The M group is then separated in subtypes, 
or clades, from A-J with B being most prevalent in developed nations (Knipe and Howley, 2001) 
(Figure 2). 
 
Figure 2: HIV-1 Subtype distribution by geography.  Map shows HIV 
subtypes by locations, the developed world is predominantly B type while Africa 
shows all three groups as well as many group M subtypes, this (Vidal, 2000). 
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HIV is the only lentivirus known to infect humans (Knipe and Howley, 2001). The 
typical course of an HIV-1 infection is highly variable with death occurring approximately a 
decade after infection (Figure 3).  The initial acute phase of the disease which happens 
immediately following infection results in rapid viral replication.  This increase in viral copy is 
accompanied by a drop in CD4+ T cells.  As the disease progresses it enters a chronic 
asymptomatic phase which is characterized by clinical latency in which viral loads drop and 
CD4+ T cells levels stabilize.  Once the T cell levels fall below 200 cells per microliter the body’s 
cell-mediated immunity is no longer functional.  At this point the disease progresses to a 
symptomatic final phase: AIDS.  The onset of AIDS is often accompanied by the infection from 
opportunistic microbes which eventually lead to death. 
 
Figure 3:  The course of HIV infection. The graph shows the levels of CD4+  
T lymphocytes, HIV RNA copies per ml of plasma, and plasma viremia over the 
course of the infection.  There are three distant phases seen, acute, asymptomatic, 
and symptomatic/AIDS (Fauci, 1996). 
 
The symptoms of the disease pathology are brought on by the underlying characteristics 
of the virus itself.  HIV uses reverse transcriptase to turn its RNA genome into DNA so that the 
host’s cells can replicate the virus.  This process is extremely error prone, making 1 mistake per 
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10,000 base pairs copied; this results in one error per round of replication.  The difficulty in 
treating HIV is that it is not one virus but rather many slightly different viruses known as 
quasispecies.  This also allows it to evade the immune system which isn’t able to keep up with all 
the variations. 
V i r a l  C o m p o s i t i o n  
 Like all retroviruses HIV contains several structural genes including: gag, pol, and env 
(Wiley, 2001).  However HIV is more complex and contains at least 6 more genes including: tat, 
rev, nef, vif, vpr, and vpu (Wiley, 2001).  These genes are summarized in Table 1 by name as well as 
the protein encoded and its function. 
Table 1: HIV Composition 
Gene Name  Proteins Encoded  
Group-specific Antigen (gag)  Structural Protein; Precursor for the Matrix 
(MA), Capsid (CA), Nucleocapsid (NC), and p6 
proteins. 
Polymerase (pol)  Structural Protein; Protease (PR), Reverse 
Transcriptase (RT), and Integrase (IN).  
Envelope (env)  Structural Protein; Envelope glycoproteins  
Trans-activator of viral transcription (tat)  Regulatory Protein; Enhances transcription. 
Regulator of Viral Protein Expression (rev)  Regulatory Protein; Regulates RNA splicing.  
Negative Factor (nef)  
 
Accessory Protein; Enhances viral replication. 
Down modulation and degradation of CD4 and 
MHC class I.  
Virus Infectivity Factor (vif)  Accessory Protein; Crucial for infectious virons 
specific to cell type. Causes degradation of host 
defense protein, APOBEC 3G. 
Viral Protein R (vpr)  Accessory Protein; Stimulates viral gene 
expression. Important for infection of non-
dividing cells.  
Viral protein U (vpu)  Accessory Protein; Enhances virus release by 
removing tetherin from the cell surface. Also 
degrades CD4. 
 (Tables contents from: Wiley, 2001; Knipe and Howley, 2001). 
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S t r u c t u r a l  P r o t e i n s  –  g a g ,  p o l  a n d  e n v  
 The HIV-1 genome contains the same structural proteins as other retroviruses and are 
created via a polyprotein precursor (Knipe and Howley, 2001).  The first of these is the group 
specific antigen (gag) protein which is cleaved to form four other proteins: matrix (MA), capsid 
(CA or p24), nucleocapsid (NC) and p6 proteins (Watts, 2009).  The MA protein is important 
for targeting gag and gag-pol precursor polyproteins into the plasma membrane prior to viral 
assembly (Frankel 1998).  The CA protein forms the core of the virus and also contains some of 
the most highly conserved domains of the virus (Frankel 1998).  The NC protein is the third 
part of the gag  polyprotein and its primary role is to bind to the packaging signal and deliver two 
copies of full-length RNA into the assembling virion (Frankel 1998).  Figure 4 shows the 
genome of HIV-1 as well as the locations of each of the related proteins. 
 
 
Figure 4: Map of the HIV genome. Organization of the HIV-1 genome and 
virion (Frankel, 1998). SU = gp120, TM = pg41. 
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 The second of the precursor proteins is polymerase (pol) which is cleaved to form three 
proteins: viral protease (PR), reverse transcriptase (RT), and intergrase (IN) (Watts, 2009).  PR 
functions as a dimer enzymatically cleaving polyproteins to produce MA, CA, NC, p6, PR, RT 
and IN proteins (Frankel 1998).  PR is a prime site for chemotherapy research because of its 
importance in the replication phase of the virus (Frankel, 1998).  Prior to integration into the 
hosts chromosome, the viral RNA must first be reverse transcribed into dsDNA, this is the role 
of RT (Frankel, 1998).  RT is also the primary cause of genetic variation and as such is also a 
target of drug design (Frankel 1998).  The IN protein catalyzes a series of reactions which 
integrates the viral genome into the host chromosome (Frankel 1998) and has recently been 
targeted for anti-HIV drugs.  
 The envelope (env) gene is the last of the structural polyproteins and produces gp120 and 
gp41 (Watts, 2009).   These proteins are grouped into trimers on the virion which consists of a 
gp120 surface protein and a gp41 transmembrane subunit (Dunfee, 2006).  These are both 
formed from the precursor, gp160 being cleaved in the golgi apparatus (Clapham and McKnight, 
2002).  The gp120 protein is the focus of much research because it facilitates entry into the 
target cell.  It also contains five variable loops which can modulate the tropism of the virus 
(Figure 5). 
 
Figure 5: The Envelope Gene.  The polyprotein env is cleaved to form gp120 
and gp41.  The figure shows the location of the variable loops. The env gene also 
encodes the rev response element (RRE), an RNA structure involved in nuclear 
export of HIV transcript. Numbers represent the nucleotide sequence (LANL). 
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R e g u l a t o r y  P r o t e i n s  
 The HIV genome also includes two regulatory proteins: the transactivator of viral 
transcription (tat) and the regulator of viral protein expression (rev).  The tat protein up regulates 
the production of viral mRNAs up to 100 fold.  It does not bind to DNA but instead to an 
RNA hairpin known as the trans-activating response element or TAR (Frankel 1998).  Without 
tat, RNA polymerase II will only transcribe for a few hundred nucleotides (Frankel 1998).  The 
second regulatory protein, rev, contains a nuclear export signal which allows it to shuttle between 
the nucleus and cytoplasm (Frankel, 1998).  Rev binds the RRE present on incompletely or 
unspliced viral mRNA allowing it to be exported from the nucleus without extensive splicing 
(Frankel 1998). 
A c c e s s o r y  P r o t e i n s  
 HIV-1 also has four accessory proteins that are unique to lentiviruses and do not appear 
to be necessary for viral replication in vitro; they are: nef, vif, vpr, and vpu.  Both nef and vpu down 
regulate cellular levels of CD4 (Frankel, 1998).  This is beneficial to the virus because the gp160 
precursor protein is sometimes held in the endoplasmic reticulum through interaction with 
newly synthesized CD4 molecules (Frankel, 1998).  The vif protein disrupts the human antiviral 
protein APOBEC and also has some role in the assembly or maturation of the virus (Rose, 
2004; Frankel 1998).  The vpr protein mediates the rapid transportation of nucleoprotein 
complexes following the fusion and entry into the cell (Frankel 1998).  Vpr’s nuclear localization 
ability is especially important in non-dividing cells such as macrophages (Frankel, 1998). 
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V i r a l  E n t r y  
The entry of the HIV virion into the cell is mediated by the high affinity interaction 
between gp120 and CD4 which induces a conformational change in the structure of gp120 and 
exposes the co-receptor binding site (Dunfee, 2006).  This then leads to a conformational 
change in gp41 which enables fusions and entry into the cell (Dunfee, 2006).  The variable loops 
discussed above may help the virus to escape antibody-mediated neutralization (Clapham and 
McKnight, 2002). 
The CD4 receptor which is used by HIV-1 to gain entry to the cell is most commonly 
found in the following cells: T helper cells, regulatory T cells, monocytes, macrophages, and 
dendritic cells.  In the body, CD4 recognizes class II major histocompatibility complex (MHC) 
molecules (Ryu, 1990).  This recognition plays a role in mediating an efficient immune response 
however it can also be subverted to become the receptor for HIV-1 infection (Ryu, 1990).  HIV-
1 is usually unable to infect cells without CD4, this signifies that the presence of CD4 is a major 
determinant of HIV-1 tropism. 
C o - r e c e p t o r  a n d  T r o p i s m  
 As discussed the primary receptor for HIV is CD4, however in order for the virion to 
enter the cell a coreceptor is needed.  This is fulfilled by seventransmembrane (7TM) chemokine 
receptors, either CCR5 (R5) or CXCR4 (X4).  In some cases a virus is able to use both of these 
receptors.  It has been suggested that it is possible for HIV-1 to use other 7TM chemokine 
receptors in vitro however their significant use in vivo is not currently supported (Clapham and 
McKnight, 2002).  R5 viruses infect memory T-cells and primary macrophages while X4 viruses 
mainly target naïve T-cells.  This makes the co-receptor a secondary determinant of tropism. 
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 The co-receptor is especially important in deciding what type of T-cell the virus can 
infect.  The main receptor for transmitted variants of HIV-1 is R5 with X4 viruses often 
becoming detectable with the onset of AIDS which leads to the rapid decline of CD4+  T-cells 
and eventually death (Caverell, 2009).  However the ability of R5 viruses to infect primary 
macrophages is highly divergent and varies over 1000 fold (Musich 2010).  Several mutations in 
R5 viruses have been identified which increase the macrophage tropism; these include E153G 
and T283N mutations. 
 
Figure 6: HIV-1 Co-receptor usage.  HIV-1 is able to use either X4, R5, or a 
combination of co-receptors to infect an array of CD4 producing cells (Berger, 1999) 
 
E 1 5 3 G  M u t a t i o n  
 It has recently been reported by Musich et al. that a single point mutation at residue 153 
in the V1 loop can modulates macrophage-tropism (Musich 2010).  It was reported that there 
were dramatic shifts in sensitivity to soluble CD4 (sCD4) and a V3 loop mab 447-52D as well as 
modest shifts in b12 sensitivity (Musich, 2010).  It is possible that the shift in sCD4 suggests a 
conformational change which allows binding to suboptimal levels of CD4 (Musich, 2010). 
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Table 2: E153G Amino Acid Comparison 
Amino 
Acid 
Glutamic acid (E) Glycine (G) 
Structure 
  
T 2 8 3 N  M u t a t i o n  
Amino acid location 283 is one part of the conformational CD4 binding site on gp120.  
It has been shown that when this location is an asparagine (N) gp120’s affinity for CD4 is 
increased (Dunfee, 2006).  This mutation has been reported to occur specifically in viruses 
associated with brain envelopes involved in dementia (Dunfee, 2006).  It has also been shown 
that the introduction of this mutation into an envelope with T or I resulted in increased 
macrophage tropism (Duenas-Decamp, 2009).  It is possible that this increased affinity is the 
result of asparagines ability to form an additional hydrogen bond with Q40 on CD4 as seen in 
Table 3 (Dunfee, 2006). 
Table 3: T283NAmino Acid Comparison 
Amino 
Acid 
Asparagine (N) Threonine (T) 
Structure 
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Functional 
difference 
  
The T283N change increases the potential for a hydrogen bond from Q40 to 
CD4 (Dunfee et al, 2006). 
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PROJECT PURPOSE  
 The purpose of this MQP is to investigate two known mutations to the HIV-1 envelope 
gene that can affect its macrophage-tropism.  The first was recently identified by the Clapham 
Lab and is an E153G mutation which is located in the V1 loop of gp120.  The second mutation 
is in the CD4 binding site of gp120 which was shown to be present in later stages of the disease, 
in particular those with HIV-associated dementia.  This mutation has been shown to increase 
affinity for cells with low levels of CD4, thus making them more macrophage-tropic (N283 
Citation).  This project will explore if these point mutations alone are responsible for this 
increase in tropism.  The virus panel used includes samples from early transmitted virus. Our 
aim was to establish whether these determinants were involved in the non-macrophage-tropic 
phenotype of transmitted R5 viruses, or affected their sensitivity to entry inhibitors. 
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MATERIALS AND METHODS 
S e l e c t i o n  o f  V i r u s  E n v e l o p e s  
 Virus envelopes were selected from a panel of HIV-1 subtype B envelopes provided by 
the NIH AIDS Research and Reference Reagent Program.  The envelopes 6T and 20T were 
selected for their resistance to sCD4 and b12 while 11T and 15T were selected for their 
sensitivity.  In addition two of the envelopes contained the point mutations of interest and were 
included as controls (5T and 9T).  Other envelopes were used in some experiments as known 
controls, these are: LN8, LN40, B59 and VSVG.  
 Table 4: Envelopes 
 Env Clone Name IC50 
b12 
ug/ml 
IC50 
sCD4 
ug/ml 
Coreceptor Residues 
Short Long 153 283 
T
ra
n
sm
it
te
d
 
P
a
n
e
l 
E
n
v
e
lo
p
e
s 
6T 63358-04.P3.4013 >50 538 R5 E T 
20T PCB931-06.7C3.4930 22.7 1000 R5 E T 
11T PRB926-04.A9.4237 0.5 93 R5 E T 
15T 700010040.C9.4520 0.7 97 R5 E T 
5T 1012-11.TC21.3257 >50 331 R5 E N 
9T 62357_14.D3.4589 47.5 83 R5 G T 
P
a
ti
e
n
t 
C
o
n
tr
o
ls
 
E
n
v
s.
 
LN8       
LN40       
B59       
VSVG       
 
D N A  P r e p a r a t i o n  a n d  C o n s t r u c t i o n  o f  C l o n e s  w i t h  S i n g l e  P o i n t  M u t a t i o n s  
 The envelope gene is contained within a pcDNA3.1D plasmid which is under a CMV 
promoter and while in bacteria confers an ampicillin resistance.  Competent bacteria glycerol 
stocks are kept at -82°C and an inoculation loop was used to transfer a small amount to a 14-ml 
tube with 5 ml of LB-Ampicillin and incubated while shaking overnight.  It is then centrifuged at 
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4,000 rpm for 15 minutes and the supernatant removed.  At this point a miniprep kit from 
Qiagen was used to extract the DNA which was eluted in 60-80 µl water. 
 
Figure 7: Plasmid. The features of the pcDNA3.1D plasmid are shown.  There 
are two origins of replication which allows it to be used in both bacteria and 
mammalian cell lines. 
M u t a g e n e s i s  o f  t h e  T r a n s m i t t e d  P a n e l  E n v e l o p e  V e c t o r s  
Mutagenesis was performed using an in vitro site directed PCR technique (QuikChange 
Kit, Strategene).  Prior to this however, eight sets of mutagenic primers were designed and 
ordered through the Center for AIDS Research.  Considerations in the design of the primers 
included the following: primers between 25 and 45 bases in length with the mutation near the 
center of the primer with at least 10 base pairs of correct sequence on both sides and containing 
a minimum GC content of 40%.   This last consideration was not always possible as this region 
is very TA rich and in one case a primer of 47 base pairs was used in order to increase the GC 
concentration.  The primers used are summarized in Tables 5 & 6. 
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Table 5: E153G Mutagenic Primers 
Env Primers 
6T GGAGAGAAAGGAGGAATAAAGAACTGC 
GCAGTTCTTTATTCCTCCTTTCTCTCC 
11T GGAGAGAGGAGGAATAAAAAACTGC 
GCAGTTTTTTATTCCTCCTCTCTCC 
15T CGGGGAAATGATGGAGAAGGGAGGAGTAAAAAACTGTTCTTTCAAG 
CTTGAAAGAACAGTTTTTTACTCCTCCCTTCTCCATCATTTCCCCG 
20T CGGTGGAGAGAGCAGGAATGAAAAACTGC 
GCAGTTTTTCATTCCTGCTCTCTCCACCG 
 
Table 6: T283N Mutagenic Primers 
Env Primers 
6T CGAACAATGCCAAAAACATAATAGTACAGCTG 
CAGCTGTACTATTATGTTTTTGGCATTGTTCG 
11T CGAACAATGCTAGAAACATAATAGTACAGC 
GCTGTACTATTATGTTTCTAGCATTGTTCG 
15T GTGACAATGCTAAAACAATAATAGTACAACTG 
CAGTTGTACTATTATGTTTTTAGCATTGTCAC 
20T CGGACAATGCTAAAAACATAATAGTACAGC 
GCTGTACTATTATGTTTTTAGCATTGTCCG 
 
Once the primers were received they were diluted to 100 µM for use in PCR.  The 
sample reaction was prepared in a PCR hood using 5 µl of reaction buffer, 125 ng of 
oligonucleotide primer 1 and 125 ng of oligonucleotide 2, 1 µl of dNTP mix and 1 µl of 
PfuTurbo DNA polymerase.  The polymerase was added last to prevent the stock from being 
degraded.  The tubes were then returned to the main lab where 50 ng of dsDNA template was 
added.  The reaction was then placed in a thermocycler; the first step is an initialization step for 
30 seconds at 95°C, which activates the polymerase.  The samples are then cycled through three 
steps, denaturation of the dsDNA happens at 95°C for 30 seconds then the reaction 
temperature is dropped to 55°C which allows annealing of the primers to the DNA and then the 
temperature is raised to 68°C and the polymerase extends the primer and creates a new strand.  
The samples are cycled 20 times and then the temperature is dropped to 4°C indefinitely (at least 
2 minutes) to stop the reaction. 
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Figure 8: PCR Strategy.  Step one is initialization, step two causes denaturation 
of the DNA, step 3 causes annealing of the primers and step 3 alls the 
polymerase to extend the primer, the last step stores the new DNA at an 
appropriate temperature.  Steps 2-4 are repeated for 20 cycles. 
 
The samples are then digested using 1.5 µl of DpnI for 1 hr at 37°C to remove 
methylated nonmutated parental DNA.  Microcentrifuge tubes are then prechilled in ice and 50 
µl of XL-1 blue supercompetent cells are aliquoted into them.  To the cells is added 1.5 µl of the 
DpnI digested PCR reaction which is then incubated on ice for 30 minutes.  This is followed by 
a heat shock at 42°C for 45 seconds and put back on ice for at least 2 minutes.  Prewarmed SOC 
medium (~500 µl) is added and incubated in the 37°C shaker for at least 1 hour.  This is then 
plated at 100-300 µl onto a carbinacillin plate and incubated overnight at 37°C.  The next day 
colonies are picked and grown in 5 ml LB-amp overnight for miniprep the next morning.  The 
rest of the colonies are picked using a sterilized wooden tooth pick and placed on a gridded plate 
which also contains colonies from the colonies picked for miniprep.  The samples were then 
sent to GeneWiz for sequencing to confirm the mutations were present. 
95°C 95°C 
55°C 
68°C 
4°C 
30 Sec 30 Sec 
1 min 
1*Kbp 
~8.5 min 
∞ 
Repeat: 20 Cycles 
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P r o d u c t i o n  o f  e n v +  P s e u d o v i r i o n s  
 In order to create pseudovirions, both backbone DNA as well as env expressing plasma 
must be cotransfected into 293T cells.  The backbone is derived from the NL4.3 standard and 
contains all of the HIV-1 genes but has a premature stop codon in the env gene.  Transfections 
were preformed on 293T cells that were plated in 6-well plates at 1x105 cells/mL with 2 mL per 
well.  The medium used is Dulbecco’s Modified Eagle Medium (DMEM) with 4% Fetal Bovine 
Serum (FBS) and gentamicin.  The plates were incubated at 37°C and 5% CO2 overnight.  The 
concentration of env clone DNA as well as the backbone DNA is 1.25 µg/µl.  The transfection 
was done using two tubes each, in the first tube was both sets of DNA, 10.34 µl 2M CaCl2, and 
enough nuclease free water to bring the final volume to 83.40 µl.  The second tube contains 
83.40 µl 2X HEPES buffered saline.  The first tube was added drop wise while the second tube 
was being vortexed.  After incubating at room temperature for 30 minutes 166.8 µl from the 
tubes were added to each well of the 293T plates.  After 24 hours the medium was changed and 
the supernatant was harvested at 48 hours and clarified by centrifuging for 10 minutes at 1,200 x 
g.  This centrifuging caused all cell debris to go to the bottom of the tube, the supernatant was 
then aliquoted into 1 mL tubes and submerged in liquid nitrogen which would kill any cells that 
are left and then stored at -152° C. 
T i t r a t i o n  o n  T Z M - b l s  
 TZM-bls are a HeLa cell line, an immortal cell line derived from cervical cancer cells.  
They have a 'built in' long terminal repeat controlled β-galactosidase reporter gene which 
identifies infected cells (Wei, 2002).  Quantification relies on pseudovirions only undergoing a 
single round of replication.  Focus forming units/ml can be estimated by counting individual or 
small groups of blue spots (Duenas-Decamp, 2008).  Cells were plated at 5 x 104 cells/mL on 48 
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well plates the day prior to titration.  Four dilutions per virus were used, the first being a neat 
well with full strength virus, the second and following containing 270 µl of medium and 30 µl 
from the previous well.  A separate tip is used between each well when moving from a higher 
concentration well to a lower one to reduce contamination.  Once the dilutions were set up 
media was removed from the cells one well at a time and 100 µl of the virus dilution was added 
with two wells per dilution.  The addition of virus dilution was done from least concentrated to 
most.  The plates were placed in the incubator for 3 hours and 0.5 mL of growth medium was 
then added. 
 After 48 hours the cells were fixed and stained using the following protocol.  Media was 
removed from each well by aspiration and washed in 1x PBS.  This was aspirated and replaced 
with 0.5 mL PBS/0.5% gluteraldehyde and incubated at 4°C for 10-15 minutes which caused the 
cells to become fixed.  This was then removed by aspiration and cells were rinsed twice with 
PBS/0.1% azide.  In order to stain the cells 200 µl of yellow PBS containing 0.5 mg/ml (1:80 
dilution) of X-Gal was applied (yellow PBS contains 3mM potassium ferrcyanide, 3mM 
potassium ferrocyanide and 1mM magnesium chloride).  Plates were then incubated at room 
temperature and counted after approximately 2 hours.  The substrate solution can then be 
replaced with PBS/0.1% azide and kept at 4°C until counted. 
T i t r a t i o n  o n  M a c r o p h a g e s  
 Elutriated monocytes were provided by the University of Massachusetts Medical School 
Center for AIDS Research.  They were plated in 14 cm bacterial culture plates with DMEM with 
10% human plasma for 5-7 days in order to differentiate them into macrophages.  The plates 
were then treated with versene and a cell scraper used to remove the adhered cells and the final 
concentration was brought to 2.5 x 10^5 cells/mL.  This concentration was then plated in a 48 
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well plates and left to adhere in the incubator overnight.  The next day 100 µl of DEAE dextran 
(diluted 1:100 to 10ug/ml) with macrophage media was added to each well and incubated for 30 
minutes.  Virus was diluted and added the same as with TZM-bls and then “spinoculated” at 
1200 rpm for 45 minutes at room temperature.  After 3 hours or the next morning media was 
added and then incubated for about a week. Media is changed as necessary. 
After the week the cells are fixed using a methanol-acetone protocol and stained using an 
indirect immunostaining technique using two antibodies.  To do this media was removed from 
the cells by aspiration and rinsed with 1x PBS and then removed by aspiration again.  The cells 
were then fixed by applying 0.5 mL of methanol-acetone at -20°C for 5-10 minutes and then 
rinsed with PBS and again with PBS/0.1% azide/1% FBS.  A 1:1 mix of monoclonal antibodies 
3896K and EF7 was used to stain for p24, it was diluted 1:30 and 100 µl of the dilution was 
added to each well and incubated at room temperature for 1 hour.  The cells were then washed 
twice with PBS/0.1% azide/1%FBS.  The secondary antibody is a goat anti-mouse beta-
galactosidase conjugate, 100 µl of the antibody diluted 1:200 was added to each well and 
incubated for an hour at room temperature.  The cells were then washed once with 
PBS/0.1%azide/1% FBS and once with plain PBS.  The same x-gal staining procedure used for 
TZM-bls was then used to stain the macrophages.  The plates were then incubated at room 
temperature for at least 3 hours but not more than overnight and counted by light microscopy. 
N e u t r a l i z a t i o n  a n d  I n h i b i t i o n  A s s a y s  
In these assays different compounds are used to inhibit infection.  The three compounds 
used were: Maraviroc - a CCR5 inhibitor, b12 - a monoclonal antibody that binds to the virus 
envelope, and soluble CD4 (sCD4) - which mimics CD4 that is normally used for cell entry.  
Two hundred µl of TZM-bl cells at 1.6x10^5 cells/ml were plated in 96 well luminescence plates 
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(white wall, clear bottom) one day prior to infection.  The medium used was DMEM with 4% 
FBS and gentamicin.   The next day, a serial dilution of the treatment was created and was 
incubated with 200 FFU of virus (except for Maraviroc which was incubated with the cells) for 1 
hour at 37°C.  Medium was then aspirated off the cells and 50 µl of the virus/inhibitor mix was 
added to the cells (30 µl of virus in the case of Maraviroc) and left to incubate at 37°C for 
approximately 18 hours.  After the incubation the medium was changed (for the Maraviroc the 
inhibitor was added back in the same dilutions instead of plain medium).  The next day the 
medium was aspirated and replaced with 100 µl clear DMEM (without phenol red) and 100 µl of 
beta-glo.  Beta-glo invokes a luminescent response in the cells expressing the beta-galactosidase 
reporter gene.  The plates were then incubated in the dark at room temperature for 30 minutes 
and then read on the luminometer. 
 
Table 7: Assay Treatments – Structure and Function 
Treatment Maraviroc b12 sCD4 
Type CCR5 inhibitor  Monoclonal Antibody Glycoprotein 
Structure  
 
 
  
(HIV/MHC binding site 
shown) 
(Maraviroc – Dorr, 2005; b12 – Saphire, 2001; sCD4 – Ryu, 1994) 
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RESULTS 
 The overall goal of this project was to further examine the determinants of the HIV-1 
envelope that increase their macrophage-tropism and to establish their role in the non-
macrophage-tropic phenotype of transmitted R5 envelopes.  The first phase of the project was 
to create a total of eight mutants, four for each of the mutations being studied.  The second 
phase was to test if the genotypic change to each of the mutants caused a phenotypic change in 
macrophage infection or affected sensitivity to entry inhibitors. 
C o n s t r u c t i o n  a n d  V e r i f i c a t i o n  o f  M u t a n t  C l o n e s  
 There were two different env mutations made for each of the viruses for a total of eight 
clones.  Following the mutagenesis procedure DNA was sequenced and only sequences with the 
correct mutation were used.  Figure 9 shows the nucleotide and amino acids for one of the 
mutants (6T T283N).  These sequences were analyzed using MacVector as well as Lasergene 
MegAlign (shown in Figure 9) using the ClustalV alignment method. 
 
 
Figure 9: Sequence Confirmation.  The single point mutation in DNA (C to 
A) causes an amino acid shift from T to N in the 6T envelope gene.  Each 
mutant was confirmed like this, only this mutant is shown. 
 
+---------+---------+---------+---------+---------+---------+---------+ 
1140      1150      1160      1170      1180      1190      1200 
+---------+---------+---------+---------+---------+---------+---------+ 
6T ATTAGATCTGCAAATTTCTCGAACAATGCCAAAACCATAATAGTACAGCTGAATGAGTCTGTAAAAATTG 
62-5 ATTAGATCTGCAAATTTCTCGAACAATGCCAAAAACATAATAGTACAGCTGAATGAGTCTGTAAAAATTG 
      +---------+---------+---------+---------+---------+---------+---------+ 
     250       260       270       280       290       300       310       320 
      +---------+---------+---------+---------+---------+---------+---------+ 
6T TGQCKNVSTVHCTHGIKPVVSTQLLLNGSLAEEEVVIRSANFSNNAKTIIVQLNESVKIECMRPNNNTRKG 
62-5 TGQCKNVSTVHCTHGIKPVVSTQLLLNGSLAEEEVVIRSANFSNNAKNIIVQLNESVKIECMRPNNNTRKG 
 26 
Once the sequence was confirmed a glycerol stock of the transformed bacteria was made 
along with for each envelope+ plasmid. Plasmid DNAs encoding each env along with env-
minus pNL4.3 (to express the other HIV proteins) were then transfected into 293T cells.  
Pseduovirions were created and then titrated on TZM-bls to confirm infectivity.  TZM-bls are a 
permissive cell line as they have high levels of both CD4 and R5.  All of the mutant strains 
produced virus that was able to infect the permissive TZM-bl cell line within the same range as 
the non-mutated envelope+ viruses at or above 105 Focus Forming Units (FFU) per ml (Figure 
10).  FFU is a simple count of how many cells appear to be infected.  In this case this is then 
multiplied to account for the dilution factor.  These verified virus stocks were then used to 
perform the macrophage and neutralization/inhibition studies. 
 
Figure 9 10: TZM-bl titration on a logarithmic scale.  This data represents 
the potency of the virus stocks produced in focus forming units per ml. 
M a c r o p h a g e  S t u d i e s  
 Once the virus stocks were confirmed by TZM-bl titration they were then titrated on 
macrophages.  The mutants 6T and 15T showed at least an order of magnitude increase in 
6T 11T 15T 20T
Original 2.45E+05 2.75E+05 1.45E+05 7.50E+04
E153G 3.00E+05 2.40E+05 1.45E+05 1.45E+05
T283N 5.20E+05 6.10E+05 4.05E+05 5.40E+05
1.0E+00
1.0E+01
1.0E+02
1.0E+03
1.0E+04
1.0E+05
1.0E+06
FF
U
/m
l
TZM-bl Titration
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infectivity.  For both 6T and 15T this meant going from 10 FFU/ml to 530 and 875 FFU/ml 
respectively for the E153G mutation.  11T showed a more modest increase for the same 
mutation from 225 to 530 FFU/ml, still doubling compared to the original envelope.  For 20T 
the original envelope showed no macrophage tropism, the T283N mutation allowed a small level 
of infection.  However macrophages being primary cells that come from donors these results are 
not yet confirmed.  One of the macrophage experiments resulted in only the VSVG lane 
staining, even though there were also other macrophage tropic virus controls present.  There is 
also currently no reliable data on the T283N mutation for the 6T and 11T viruses because they 
had not yet been produced. 
 
Figure 10: Macrophage titration on a logarithmic scale.  The T283N 
mutations for 6T and 11T do not have enough reliable data to report here.  Both 
the original 20T envelope as well as the E183G mutant were unable to infect 
macrophages. 
 
6T 11T 15T 20T
Original 1.00E+01 2.25E+02 1.00E+01 0.00E+00
E183G 1.45E+02 5.30E+02 8.75E+02 0.00E+00
T283N 0 0 7.85E+02 1.50E+01
1.00E+00
1.00E+01
1.00E+02
1.00E+03
FF
U
/m
l
Macrophage Titration
NT NT
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E n v e l o p e  6 T  I n h i b i t i o n  S e n s i t i v i t y  
 The 6T envelope was chosen because of its resistance to both b12 and sCD4 (IC50 
values of >50 and 538 ug/ml).  As expected the b12 neutralization assay shows what little effect 
b12 has on the original envelope as well as the mutants.  The sCD4 assay however shows a 
marked increase in sensitivity for both the mutants particularly the E153G with 94.5% inhibition 
at the highest concentration (50ug/ml) compared with a 26.9% inhibition for the non-mutated 
envelope.  All the envelopes are sensitive to Maraviroc at higher concentrations however the 
mutants become less sensitive at lower concentration starting at 6.25 ng/ml with a 35% 
difference between the original and mutant envelopes.  At 3.13 ng/ml the difference is 78% for 
the E153G mutant and 58% for the T283N mutant.  This result was not expected for Maraviroc 
which is an R5 inhibitor, it was expected that the mutants would have the same sensitivity as the 
original envelope.  However since the values at the higher concentrations are the same it is 
possible that this finding is insignificant. 
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Figure 11: Neutralization assays using envelope 6T and its mutants.  The E153G 
mutation is represented by 61 and T283N mutation is represented by 62.  B59 is a 
positive control for b12 and sCD4, VSVG is a negative control for Maraviroc. 
 
E n v e l o p e  1 5 T  I n h i b i t i o n  S e n s i t i v i t y  
 The 15T envelope was chosen because of its sensitivity to both b12 and sCD4 (IC50 
values of 0.7 and 97).  The b12 assay shows that all of the mutants show roughly the same 
sensitivity as the original envelope.  The sCD4 assay shows a modest increase in sensitivity for 
both of the mutations.  Starting at 12.5 ng/ml this increase in sensitivity is about 12% for both 
mutants increasing to 34% for the E153G mutant and 18% for the T283N mutant at 6.25 
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ng/ml.   For 0.78 ng/ml the difference is 67% and 41% respectively.  This increase in sCD4 is 
expected however it is not as drastic as in 6T because there is no restoration of sensitivity the 
original 6T envelope is sCD4 resistant.  All the envelopes are sensitive to Maraviroc with no real 
shifts as was seen in 6T. 
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Figure 12: Neutralization assays using envelope 15T and its mutants. The E153G 
mutation is represented by 151 and T283N mutation is represented by 152.  B59 is a 
positive control for b12 and sCD4, VSVG is a negative control for Maraviroc. 
E n v e l o p e  2 0 T  I n h i b i t i o n  S e n s i t i v i t y  
 The 20T envelope was chosen because of its resistance to both b12 and sCD4 (IC50 
values of 22.7 and 1000).  As expected the b12 assay shows the little effect b12 has on the 
original envelope as well as the mutants.  The sCD4 assay also showed very little sensitivity 
which was also expected given such a high IC50 value.  The Maraviroc assay shows that the 
mutants are slightly more sensitive at lower concentrations than the original envelope.  This 
begins at 3.13 ng/ml for the E153G mutant with a 10% increase in sensitivity.  At 1.56 ng/ml 
there is a 30% increase in sensitivity for that mutant and a 9% difference for the T283N mutant.  
Like 6T this only happens at lower concentrations however since the shift is opposite that of 6T 
it is possible that both of these findings have little significance. 
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Figure 13: Neutralization assays using envelope 20T and its mutants. The E153G 
mutation is represented by 201 and T283N mutation is represented by 202.  B59 is a positive 
control for b12 and sCD4, VSVG is a negative control for Maraviroc. 
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DISCUSSION 
 The key receptor for HIV-1 infection is CD4 with a chemokine receptor also needed to 
gain entry to the cell.  In most cases of transmission the chemokine CCR5 is used however by 
the later stage of the disease 50% of AIDS patients have switched to the chemokine CXCR4 as 
the receptor.  This shift allows the infection of T-cells that do not have CCR5 and which 
normally leads to death.  Patients without any X4 virus however also develop AIDS through 
evolving a broader cell tropism.  Viruses were identified in patients with HIV associated 
dementia that had evolved a broader macrophage tropism.  This project explores the role of 
envelope determinants for the non-macrophage-tropic phenotype of transmitted R5 viruses. 
 Here, I have studied two substitutions. The first is a T283N amino acid substitution in 
the CD4bs of HIV-1 reported by Dunfee et al. to confer broader macrophage tropism.  The 
second is a distant V1 loop change, E153G, that has affects in the V3 loop as well as the CD4 
binding site and also modulates macrophage infection via low levels of CD4.  The T283N 
change is proposed to act via a mechanism in which the affinity of gp120 towards CD4 is 
increased by an additional hydrogen bond to Q40 on CD4.  The data presented here seems to 
confirm that for some viruses the T283N mutation does confer additional macrophage tropism. 
For one of two envelopes tested (15T) in which the non-mutated envelope was unable to infect 
macrophages, both E153G and T283N conferred substantial increases in macrophage 
infectivity. In contrast, T283N conferred only a modest increase in macrophage infectivity for 
20T, while E153G had no effect. These observations indicate the presence of other unknown 
and dominant determinants in 20T that maintain the non-macrophage-tropic phenotype.  
 Previously, non-macrophage-tropic envelopes were shown to be highly resistant to sCD4 
inhibition (Peters et al, 2008), while macrophage-tropic envs were generally sensitive. Of the 
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three non-macrophage-tropic envelopes tested here (6T, 15T and 20T), two were resistant to 
sCD4 and the third highly sensitive.  Both E153G and T283N increased sCD4 sensitivity for 6T. 
However, neither 15T (sCD4 sensitive) nor 20T (sCD4 resistant) showed altered sCD4 
sensitivity following E153G and T283N substitutions. The results are interesting and suggest 
that transmitted envelopes may have distinct properties from late disease stage envelopes 
previously studied by this lab (Peters et al. 2008). Neither E153G nor T283N affected sensitivity 
to b12, an indicator of the exposure of the CD4 binding site, while shifts in Maraviroc sensitivity 
were minor.  
Further macrophage experiments are needed to confirm the results presented and to 
evaluate the effect of donor variation.  There is no reliable data available for the T283N 
mutation for 6T or 11T because they were more difficult to make and were not yet produced 
when the reliable macrophage studies were done.   
The data presented as well as that by Dunfee et al. and Musich et al. show that a single 
amino acid substitution are able to modulate macrophage tropism for some clade B R5 
envelopes.  The data showing that neither T283N nor E153G have major affects on the non-
macrophage-tropism of 20T especially interesting. The non-macrophage-tropism of this 
envelope may therefore be determined by other envelope sites that are dominant over changes 
at 153 and 283. Further investigation is therefore warranted to identify such determinants. It is 
also not known if substitutions at 153 and 283 are complementary so the affects of double 
mutations should also be examined.  For example, the data presented here is consistent with the 
possibility that the T283N mutation is a determinant of macrophage tropism while the E153G is 
able to modulate or over-ride that tropism.  This is supported by the proposed mechanisms 
 35 
given by Dunfee et al. and Musich et al. in which the T283N enhanced CD4 binding site may be 
protected by the V3 loop via changes at residue 153. 
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